Cumberland (NASDAQ: CPIX) CEO A.J. Kazimi reports routine tax-withholding share disposition

Rhea-AI Filing Summary

Cumberland Pharmaceuticals chairman and CEO A.J. Kazimi reported a tax-related share disposition. On this Form 4, 5,845 shares of Common Stock were withheld at $3.06 per share to cover tax obligations. After this non-market transaction, he directly holds 5,695,310 shares of Cumberland Pharmaceuticals.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider KAZIMI A J

Role Chairman and CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	5,845	$3.06	$18K

Holdings After Transaction: Common Stock — 5,695,310 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAZIMI A J

(Last) (First) (Middle)

1600 WEST END AVE.

SUITE 1300

(Street)

NASHVILLE TENNESSEE 37203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		F		5,845	D	$3.06	5,695,310	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	A.J. Kazimi by /s/ John Hamm as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cumberland Pharmaceuticals (CPIX) report on this Form 4?

Cumberland Pharmaceuticals reported a tax-withholding transaction by A.J. Kazimi. A total of 5,845 Common Stock shares were disposed of to cover tax obligations, rather than sold on the open market, as part of routine equity compensation-related activity.

Who is A.J. Kazimi in relation to Cumberland Pharmaceuticals (CPIX)?

A.J. Kazimi is the chairman, CEO, and a more-than-10% owner of Cumberland Pharmaceuticals. His Form 4 filing reflects activity in his directly held Common Stock position tied to tax withholding, rather than an open-market buy or sell decision.

How many Cumberland Pharmaceuticals (CPIX) shares were involved in the latest insider transaction?

The transaction involved 5,845 shares of Cumberland Pharmaceuticals Common Stock. These shares were used to satisfy tax liabilities, according to the Form 4, and not sold in an open-market trade, making this a routine tax-withholding disposition.

What price per share was used in the Cumberland Pharmaceuticals (CPIX) tax-withholding transaction?

The Form 4 lists a price of $3.06 per share for the 5,845 shares used to cover tax liabilities. This figure is an accounting price for the tax-withholding disposition, not necessarily an indication of a market trade execution price.

How many Cumberland Pharmaceuticals (CPIX) shares does A.J. Kazimi hold after this Form 4 transaction?

After the tax-withholding disposition, A.J. Kazimi directly holds 5,695,310 shares of Cumberland Pharmaceuticals Common Stock. This post-transaction holding figure, disclosed in the Form 4, shows his remaining equity stake following the routine tax-related share withholding.

Was the Cumberland Pharmaceuticals (CPIX) insider transaction an open-market sale?

No, the transaction was not an open-market sale. The Form 4 classifies it as a tax-withholding disposition under code “F,” meaning shares were delivered to satisfy tax obligations related to equity compensation, rather than being voluntarily sold on the market.